Shares jumped 6% in premarket trading after the Food and Drug Administration approved a treatment for [schizophrenia patients]( ...
Cobenfy is the first FDA-approved antipsychotic that targets cholinergic receptors instead of dopamine receptors.
Alembic Pharmaceuticals has announced that it has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Paliperidone ...
Bristol-Myers Squibb shares rose in premarket trade on Friday after the Food and Drug Administration approved a schizophrenia ...
Emraclidine (formerly CVL-231) is a selective muscarinic M4 receptor-positive allosteric modulator (PAM) currently in two ...